Measuring inconsistency in meta-analyses
Reads0
Chats0
TLDR
A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.Abstract:
Cochrane Reviews have recently started including the quantity I 2 to help readers assess the consistency of the results of studies in meta-analyses. What does this new quantity mean, and why is assessment of heterogeneity so important to clinical practice?
Systematic reviews and meta-analyses can provide convincing and reliable evidence relevant to many aspects of medicine and health care.1 Their value is especially clear when the results of the studies they include show clinically important effects of similar magnitude. However, the conclusions are less clear when the included studies have differing results. In an attempt to establish whether studies are consistent, reports of meta-analyses commonly present a statistical test of heterogeneity. The test seeks to determine whether there are genuine differences underlying the results of the studies (heterogeneity), or whether the variation in findings is compatible with chance alone (homogeneity). However, the test is susceptible to the number of trials included in the meta-analysis. We have developed a new quantity, I 2, which we believe gives a better measure of the consistency between trials in a meta-analysis.
Assessment of the consistency of effects across studies is an essential part of meta-analysis. Unless we know how consistent the results of studies are, we cannot determine the generalisability of the findings of the meta-analysis. Indeed, several hierarchical systems for grading evidence state that the results of studies must be consistent or homogeneous to obtain the highest grading.2–4
Tests for heterogeneity are commonly used to decide on methods for combining studies and for concluding consistency or inconsistency of findings.5 6 But what does the test achieve in practice, and how should the resulting P values be interpreted?
A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. The usual test statistic …read more
Citations
More filters
Journal ArticleDOI
Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians
Norihiro Kato,Fumihiko Takeuchi,Yasuharu Tabara,Tanika N. Kelly,Min Jin Go,Xueling Sim,Wan Ting Tay,Chien Hsiun Chen,Chien Hsiun Chen,Yi Zhang,Ken Yamamoto,Tomohiro Katsuya,Mitsuhiro Yokota,Young-Jin Kim,Rick Twee-Hee Ong,Toru Nabika,Dongfeng Gu,Li Ching Chang,Yoshihiro Kokubo,Wei Huang,Keizo Ohnaka,Yukio Yamori,Eitaro Nakashima,Cashell E. Jaquish,Jong-Young Lee,Mark Seielstad,Masato Isono,James E. Hixson,Yuan-Tsong Chen,Tetsuro Miki,Xueya Zhou,Takao Sugiyama,Jae Pil Jeon,Jianjun Liu,Ryoichi Takayanagi,Sung Soo Kim,Tin Aung,Tin Aung,Yun Ju Sung,Xuegong Zhang,Tien Yin Wong,Tien Yin Wong,Tien Yin Wong,Bok Ghee Han,Shotai Kobayashi,Toshio Ogihara,Dingliang Zhu,Naoharu Iwai,Jer-Yuarn Wu,Jer-Yuarn Wu,Yik Ying Teo,E. Shyong Tai,Yoon Shin Cho,Jiang He +53 more
TL;DR: A meta-analysis of genome-wide association studies of systolic (SBP) and diastolic (DBP) blood pressure in 19,608 subjects of east Asian ancestry followed up with de novo genotyping and further replication in east Asian samples provides new insights into blood pressure regulation and potential targets for intervention.
Journal ArticleDOI
Placebo interventions for all clinical conditions.
TL;DR: No statistically significant effect of placebo interventions is found in four clinical conditions that had been investigated in three trials or more: pain, nausea, smoking, and depression, but confidence intervals were wide.
Journal ArticleDOI
Adiposity and cancer at major anatomical sites: umbrella review of the literature.
Maria Kyrgiou,Maria Kyrgiou,Ilkka Kalliala,Georgios Markozannes,Marc J. Gunter,Evangelos Paraskevaidis,Hani Gabra,Hani Gabra,Pierre Martin-Hirsch,Konstantinos K. Tsilidis,Konstantinos K. Tsilidis +10 more
TL;DR: Obesity is becoming one of the biggest problems in public health; evidence on the strength of the associated risks may allow finer selection of those at higher risk of cancer, who could be targeted for personalised prevention strategies.
Journal ArticleDOI
Epidemiology of traumatic brain injury in Europe.
Wouter Peeters,Ruben van den Brande,Suzanne Polinder,Alexandra Brazinova,Ewout W. Steyerberg,Hester F. Lingsma,Andrew I R Maas +6 more
TL;DR: Changes in epidemiological patterns are found: falls are now the most common cause of TBI, most notably in elderly patients, andpretation of published epidemiologic studies is confounded by differences in inclusion criteria and case ascertainment.
Journal ArticleDOI
The Health Benefits of Muscular Fitness for Children and Adolescents: A Systematic Review and Meta-Analysis
Jordan J. Smith,Narelle Eather,Philip J. Morgan,Ronald C. Plotnikoff,Avery D. Faigenbaum,David R. Lubans +5 more
TL;DR: Strong evidence was found for an inverse association between MF and total and central adiposity, and CVD and metabolic risk factors, and musculoskeletal pain, psychological health and cognitive ability.
References
More filters
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The combination of estimates from different experiments.
TL;DR: The problem of making a combined estimate has been discussed previously by Cochran and Yates and Cochran (1937) for agricultural experiments, and by Bliss (1952) for bioassays in different laboratories as discussed by the authors.
Journal ArticleDOI
Tamoxifen for early breast cancer: An overview of the randomised trials
TL;DR: The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and these benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose, and of whether chemotherapy had been given to both groups.
Journal Article
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
TL;DR: There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented in this paper, which approximately doubles the amount of evidence from trials of about 5 years of tamoxifier and, taking all trials together, on events occurring more than 5 years after randomisation.
Journal ArticleDOI
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.
TL;DR: In this paper, the authors evaluated standard error, precision (inverse of standard error), variance, inverse of variance, sample size and log sample size (vertical axis) and log odds ratio, log risk ratio and risk difference (horizontal axis).